(via NewsDirect)
Emyria Ltd (ASX:EMD) MD Michael Winlo speaks with Proactive following the Therapeutic Goods Administration (TGA)’s decision to down-schedule MDMA and psilocybin to Schedule 8 'Controlled Medicines' from July 2023. Winlo says the clinical-stage biotech, backed by Australian billionaire Andrew Forrest, is well-positioned to accelerate patient access to MDMA-assisted therapies. Rescheduling MDMA opens a pathway to registration and reimbursement for MDMA and its analogues.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases